ScoreWhy is Humacyte, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 23.55% and Operating profit at -195.80% over the last 5 years
2
Positive results in Mar 26
- NET SALES(HY) At USD 0.96 MM has Grown at 86.07%
- NET PROFIT(HY) Higher at USD -64.3 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 1.91 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -68.71%, its profits have risen by 0.9%
4
High Institutional Holdings at 44.23%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 0.92% over the previous quarter.
5
Below par performance in long term as well as near term
- Along with generating -68.71% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Humacyte, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Humacyte, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Humacyte, Inc.
-68.71%
-0.78
115.52%
S&P 500
20.78%
1.56
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
23.55%
EBIT Growth (5y)
-195.80%
EBIT to Interest (avg)
-13.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
44.23%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-27.44
EV to EBIT
-1.27
EV to EBITDA
-1.37
EV to Capital Employed
-134.17
EV to Sales
85.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
NET SALES(HY)
At USD 0.96 MM has Grown at 86.07%
NET PROFIT(HY)
Higher at USD -64.3 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 1.91 times
DEBTORS TURNOVER RATIO(HY)
Highest at 4.37 times
-7What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -101.53 MM
ROCE(HY)
Lowest at -409.47%
RAW MATERIAL COST(Y)
Grown by 10.19% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at 148.12 %
Here's what is working for Humacyte, Inc.
Net Sales
At USD 0.96 MM has Grown at 86.07%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -64.3 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Inventory Turnover Ratio
Highest at 1.91 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 4.37 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Humacyte, Inc.
Operating Cash Flow
Lowest at USD -101.53 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at 148.12 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 10.19% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
